Ado-trastuzumab emtansine (T-DM1), trastuzumab linked to the chemotherapy anti-microtubule agent emtansine, was the first approved ADC therapy as a second-line treatment option for HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.